2-Amino-3-(4-nitro-phenyl)-bernsteinsaeure | 3152-21-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-Amino-3-(4-nitro-phenyl)-bernsteinsaeure
• 英文别名: 3-(4-Nitrophenyl)aspartic acid；2-amino-3-(4-nitrophenyl)butanedioic acid
• CAS: 3152-21-4
• 化学式: C₁₀H₁₀N₂O₆
• 分子量: 254.199
• InChiKey: XTVUQRMWMZQWHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  146
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Therapeutic strategies for treating mitochondrial disorders
  申请人：Whitehead Institute for Biomedical Research

  公开号：US10123985B2

  公开（公告）日：2018-11-13

  Provided herein are methods, compositions, and systems for treating mitochondrial disorders (e.g., MERRF, MELAS, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia, diabetes mellitus and deafness, lactic acidosis, Leber's hereditary optic neuropathy, Wolff-Parkinson-White syndrome, Leigh syndrome, NARP, myoneurogenic gastrointestinal encephalopathy, mitochondrial DNA depletion syndrome) or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease) by administering aspartate, or an analog or prodrug thereof, or an agent that increases intracellular levels of aspartate. Pharmaceutical compositions and kits for use in treating mitochondrial disorders and neurodegenerative diseases are also described herein. Also provided are methods for treating disease by modulating the redox state of a cell, and methods of treating a proliferative disease by administering a cytosolic aspartate aminotransferase (GOT1) inhibitor.

  本文提供了用于治疗线粒体疾病（例如MERRF、MELAS、Kearns-Sayre 综合征、慢性进行性外眼肌麻痹、糖尿病和耳聋、乳酸酸中毒、Leber 遗传性视神经病变、Wolff-Parkinson-White 综合征、Leigh 综合征、NARP、肌神经性胃肠道脑病、线粒体 DNA 耗竭综合征）或神经退行性疾病（例如：阿尔茨海默病、帕金森病）的方法和系统、或神经退行性疾病（如阿尔茨海默氏症、帕金森氏症），方法是施用天门冬氨酸或其类似物或原药，或增加细胞内天门冬氨酸水平的制剂。本文还描述了用于治疗线粒体疾病和神经退行性疾病的药物组合物和试剂盒。还提供了通过调节细胞的氧化还原状态治疗疾病的方法，以及通过施用细胞质天冬氨酸氨基转移酶（GOT1）抑制剂治疗增殖性疾病的方法。
• THERAPEUTIC STRATEGIES FOR TREATING MITOCHONDRIAL DISORDERS
  申请人：Whitehead Institute for Biomedical Research

  公开号：US20160354332A1

  公开（公告）日：2016-12-08

  Provided herein are methods, compositions, and systems for treating mitochondrial disorders (e.g., MERRF, MELAS, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia, diabetes mellitus and deafness, lactic acidosis, Leber's hereditary optic neuropathy, Wolff-Parkinson-White syndrome, Leigh syndrome, NARP, myoneurogenic gastrointestinal encephalopathy, mitochondrial DNA depletion syndrome) or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease) by administering aspartate, or an analog or prodrug thereof, or an agent that increases intracellular levels of aspartate. Pharmaceutical compositions and kits for use in treating mitochondrial disorders and neurodegenerative diseases are also described herein. Also provided are methods for treating disease by modulating the redox state of a cell, and methods of treating a proliferative disease by administering a cytosolic aspartate aminotransferase (GOT1) inhibitor.